当前位置: 首页 >> 检索结果
4062. Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis.
作者: Xiangpeng Wang.;Ziyi Tang.;Tianwen Huang.;Huifang Hu.;Yaxi Zhao.;Yi Liu.
来源: Rheumatology (Oxford). 2023年62卷4期1410-1416页
To evaluate the effect of MTX withdrawal on disease activity and remission rate in patients at target after treatment with biologic DMARDs (bDMARDs)/targeted synthetic DMARDs (tsDMARDs) plus MTX.
4063. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.
作者: Sinead Maguire.;Samar Al-Emadi.;Paula Alba.;Mathia Cecilia Aguiar.;Talal Al Lawati.;Gelsomina Alle.;Bonnie Bermas.;Suleman Bhana.;Anic Branimir.;Inita Bulina.;Megan Clowse.;Karina Cogo.;Iris Colunga.;Claire Cook.;Karen J Cortez.;Kathryn Dao.;Milena Gianfrancesco.;Monique Gore-Massey.;Laure Gossec.;Rebecca Grainger.;Jonathon Hausman.;Tiffany Y T Hsu.;Kimme Hyrich.;Carolina Isnardi.;Yumeko Kawano.;Rachael Kilding.;Daria A Kusevich.;Saskia Lawson-Tovey.;Jean Liew.;Eoghan McCarthy.;Anna Montgumery.;Sebastian Moyano.;Noreen Nasir.;Ivan Padjen.;Charalampos Papagoras.;Naomi J Patel.;Mariana Pera.;Cecilia Pisoni.;Guillermo Pons-Estel.;Antonio L Quiambao.;Rosana Quintana.;Eric Ruderman.;Sebastian Sattui.;Veronica Savio.;Savino Sciascia.;Marieta Sencarova.;Rosa Serrano Morales.;Faizah Siddique.;Emily Sirotich.;Jeffrey Sparks.;Anja Strangfeld.;Paul Sufka.;Helen Tanner.;Yohana Tissera.;Zachary Wallace.;Marina L Werner.;Leanna Wise.;Angus B Worthing.;JoAnn Zell.;Julija Zepa.;Pedro M Machado.;Jinoos Yazdany.;Philip Robinson.;Richard Conway.
来源: Rheumatology (Oxford). 2023年62卷4期1621-1626页
To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.
4064. Individual participant data meta-analysis of metabolomics on sustained knee pain in primary osteoarthritis patients.
作者: Christie A Costello.;Jason S Rockel.;Ming Liu.;Rajiv Gandhi.;Anthony V Perruccio.;Y Raja Rampersaud.;Nizar N Mahomed.;Proton Rahman.;Edward W Randell.;Andrew Furey.;Mohit Kapoor.;Guangju Zhai.
来源: Rheumatology (Oxford). 2023年62卷5期1964-1971页
Knee pain is the major driver for OA patients to seek healthcare, but after pursuing both conservative and surgical pain interventions, ∼20% of patients continue to report long-term pain following total knee arthroplasty (TKA). This study aimed to identify a metabolomic signature for sustained knee pain after TKA to elucidate possible underlying mechanisms.
4067. An ankylosing spondylitis risk variant alters osteoclast differentiation.
作者: Fangyi Wu.;Xuling Han.;Jing Liu.;Zhenghua Zhang.;Kexiang Yan.;Beilan Wang.;Lin Yang.;Hejian Zou.;Chengde Yang.;Wei Huang.;Li Jin.;Jiucun Wang.;Feng Qian.;Zhenmin Niu.
来源: Rheumatology (Oxford). 2023年62卷5期1980-1987页
To explore whether the variants in non MHC proteasome gene are associated with AS and explain the role of the variant in the disease.
4068. Profiling of serum oxylipins identifies distinct spectrums and potential biomarkers in young people with very early onset gout.
作者: Can Wang.;Jie Lu.;Wenyan Sun.;Tony R Merriman.;Nicola Dalbeth.;Zhongjun Wang.;Xuefeng Wang.;Lin Han.;Lingling Cui.;Xinde Li.;Aichang Ji.;Hailong Li.;Xiaopeng Ji.;Yuwei He.;Changgui Li.;Zhen Liu.
来源: Rheumatology (Oxford). 2023年62卷5期1972-1979页
Oxylipins modulate inflammation via complex pathways. The oxylipin profile in gout remains unexplored. In this study, we systemically profiled oxylipins in young men and identified new oxylipin biomarkers for clinical use in differentiating gout from hyperuricaemia.
4069. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial.
作者: Christopher P Denton.;Nicole S Goh.;Stephen M Humphries.;Toby M Maher.;Robert Spiera.;Anand Devaraj.;Lawrence Ho.;Christian Stock.;Elvira Erhardt.;Margarida Alves.;Athol U Wells.
来源: Rheumatology (Oxford). 2023年62卷5期1870-1876页
To assess associations between the extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC over 52 weeks in patients with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial.
4070. Down-regulated FcγRII expression on plasma cells is associated with the disease activity of ANCA-associated vasculitis.
作者: Chen Wang.;Yan Gong.;Ran You.;Zhi-Ying Li.;Ming-Hui Zhao.;Min Chen.
来源: Rheumatology (Oxford). 2023年62卷5期1998-2004页
Inhibitory FcγRIIB/CD32B on B cells are critical for immunity regulation to help maintain peripheral tolerance. Altered FcγRIIB expression on B cells has been observed in several autoimmune diseases, and animal studies have suggested that FcγRIIB on B cells participates in the pathogenesis of ANCA-associated vasculitis (AAV). Here, we investigated the expression of FcγRII (FcγRIIB) on various B cell subsets and the correlation of FcγRII/CD32 expression with disease activity in AAV patients.
4072. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.
作者: Lianne Kearsley-Fleet.;Eileen Baildam.;Michael W Beresford.;Sharon Douglas.;Helen E Foster.;Taunton R Southwood.;Kimme L Hyrich.;Coziana Ciurtin.
来源: Rheumatology (Oxford). 2023年62卷5期1926-1935页
Clinicians concerned about long-term safety of biologics in JIA may consider tapering or stopping treatment once remission is achieved despite uncertainty in maintaining drug-free remission. This analysis aims to (i) calculate how many patients with JIA stop biologics for remission, (ii) calculate how many later re-start therapy and after how long, and (iii) identify factors associated with re-starting biologics.
4074. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.
作者: Philip J Mease.;Iain B McInnes.;Lai-Shan Tam.;Raji Rajalingam.;Steve Peterson.;Fareen Hassan.;Soumya D Chakravarty.;Christine Contré.;Alison Armstrong.;Wolf-Henning Boehncke.;Christopher Ritchlin.
来源: Rheumatology (Oxford). 2023年62卷4期1417-1425页
The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA). The objective of this NMA update was to include new guselkumab COSMOS trial data, and two key comparators: the IL-23 inhibitor risankizumab and the Janus kinase (JAK) inhibitor upadacitinib.
4075. Comparative risk of blindness and vision-threatening ocular comorbidities in patients with Behçet's disease versus the general population.
作者: Se Rim Choi.;Joo Young Shin.;Anna Shin.;Hokyung Choung.;Se Joon Woo.;Sang Jun Park.;You-Jung Ha.;Yun Jong Lee.;Eun Bong Lee.;Jin Kyun Park.;Eun Ha Kang.
来源: Rheumatology (Oxford). 2023年62卷5期1895-1902页
To compare the risk of blindness and vision-threatening ocular comorbidities in patients with Behçet's disease (BD) vs the general population.
4077. Work participation is unaffected in Belgian spondyloarthritis patients: data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT.
作者: Ann-Sophie De Craemer.;Liselotte Deroo.;Thomas Renson.;Ine Desimpele.;Lauren Delmez.;Saskia Decuman.;Xavier Janssens.;Annelies Boonen.;Dirk Elewaut.;Philippe Carron.;Filip Van den Bosch.
来源: Rheumatology (Oxford). 2023年62卷5期1841-1850页
This study aimed to (i) investigate actual work participation in Belgian spondyloarthritis (SpA) patients compared with the general population, and (ii) identify determinants of work-related outcomes.
4078. Treating spondyloarthritis early: does it matter? Results from a systematic literature review.
作者: Dafne Capelusnik.;Diego Benavent.;Désirée van der Heijde.;Robert Landewé.;Denis Poddubnyy.;Astrid van Tubergen.;Louise Falzon.;Victoria Navarro-Compán.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2023年62卷4期1398-1409页
To summarize evidence on the relationship between early treatment (definition based on symptom/disease duration or radiographic damage) and treatment clinical response in patients with SpA.
4079. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.
作者: Michele Iudici.;Denis Mongin.;Elise Siegert.;Patricia E Carreira.;Jörg Distler.;Jörg Henes.;Elisabetta Zanatta.;Eric Hachulla.;Giacomo De Luca.;Carolina de Souza Müller.;Tânia Santiago.;José-Luis Tandaipan.;Breno Valdetaro Bianchi.;Maria De Santis.;Anna-Maria Hoffmann-Vold.;Armando Gabrielli.;Oliver Distler.;Delphine Sophie Courvoisier.; .
来源: Rheumatology (Oxford). 2023年62卷4期1559-1567页
To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries.
4080. SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis.
作者: Eri Itotagawa.;Yoshihiko Tomofuji.;Yasuhiro Kato.;Hachiro Konaka.;Kohei Tsujimoto.;JeongHoon Park.;Daiki Nagira.;Takehiro Hirayama.;Tatsunori Jo.;Toru Hirano.;Takayoshi Morita.;Masayuki Nishide.;Sumiyuki Nishida.;Yoshihito Shima.;Masashi Narazaki.;Yukinori Okada.;Hyota Takamatsu.;Atsushi Kumanogoh.
来源: Rheumatology (Oxford). 2023年62卷5期1988-1997页
B-cell activating factor (BAFF) is implicated in SLE pathogenesis. Blocking BAFF signalling has contributed to reducing glucocorticoid dosage and preventing organ damage. However, clinical characteristics of patients who may benefit from this therapy are not yet fully elucidated. Therefore, we identified patients with high BAFF-bioactivity to investigate their clinical characteristics and BAFF-producing cells.
|